This program leverages a considerable chemistry program developed for the CD36 program in dry AMD and is meant to further exploit its outcomes. The goal of the program is to investigate the observed beneficial effects of CD36-targeting peptides in animal models of atherosclerosis and endothelial dysfunction. Lead candidate(s) have been tested alongside a statin, which represents the standard of care in atherosclerosis. This program, led by Drs. Huy Ong, William Lubell and Sylvie Marleau from the Université de Montréal, has been spun out into Mperia Therapeutics; an AmorChem start-up company.